Leerink Partners keeps Boston Scientific at Outperform, cuts target to $50
Leerink Partners kept its Outperform rating on Boston Scientific shares and lowered the price target to $50 from $55.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Leerink Partners has maintained its Outperform rating on Boston Scientific shares, according to Dow Jones Newswires. At the same time, the firm reduced its price target to $50 per share from $55.
The rating change also appears in a Benzinga overview that tracks analyst actions on the stock.
why it matters
A single price target change from one brokerage usually has a modest effect on the share price. A lower target with an unchanged rating points to a more cautious view of the stock without a shift in the analyst's overall stance.
tags
instruments
sources
- Boston Scientific Is Maintained at Outperform by Leerink Partners — Dow Jones Newswires, 29 October 2026 at 19:04 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗